Reduction in patient-reported acute morbidity in prostate cancer patients treated with 81-Gy Intensity-modulated radiotherapy using reduced planning target volume margins and electromagnetic tracking: assessing the impact of margin reduction study.
Urology., May;75(5):1004-8 (2010)
Current status of radiation therapy for bladder cancer.
Expert Rev Anticancer Ther., Jun;10(6):895-901 (2010)
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
J. Clin. Oncol., Jan;26(2):313-25 (2008)
Treatment strategies for high-risk locally advanced prostate cancer.
Nat Rev Urol., Jan;7(1):31-8 (2010)
Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost.
Int. J. Radiat. Oncol. Biol. Phys., Jan;76(1):36-42 (2010)
Radiotherapy and short-term androgen deprivation for localized prostate cancer.
N. Engl. J. Med., Jul;365(2):107-18 (2011)
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-ris
Int. J. Radiat. Oncol. Biol. Phys., Mar;73(3):672-8 (2009)
Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials.
J. Urol., Dec;176(6 Pt 2):S16-20 (2006)
Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients.
Prostate Cancer Prostatic Dis., 7(4):343-9 (2004)
Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.
J. Clin. Oncol., Jun;22(11):2133-40 (2004)